January 28, 2016 Adoption of GeneStrat by oncologists is helping to drive greater adoption of VeriStrat, Biodesix’s proteomic test for assessing a patient’s prognosis and predicting response to drug treatment.
September 4, 2015 “Biodesix discovers and commercializes cancer tests that help patients and their doctors make more informed decisions about treatment based on a patient’s unique molecular profile….” Read more at inc.com
TERMS and CONDITIONS
This site is for informational purposes only and is not intended to be a substitute for medical advice from a physician. Please check with ... Read more
April 9, 2015
The VeriStrat proteomic test, when used to help guide treatment of patients with advanced non-small cell lung cancer, improves overall survival and decreases medical costs in the U.S. payer system, said a study published recently in the journal Lung Cancer.
“Systems of care ... Read more
May 21, 2015
Diagnostic Test Reveals Actionable Mutations; Results Returned Within 72 Hours
Biodesix, Inc. today announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The blood test results are ... Read more
May 12, 2015 Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from United Healthcare (NYSE: UNH), one of the largest commercial insurance company in the US, with a published 44.7 million covered lives. In its Medical Policy (#2015T0535EE), United Healthcare describes VeriStrat as “…proven for guiding treatment decisions in patients with advanced non-small cell lung ... Read more
September 24, 2014
VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify ... Read more